Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2019-05-06 Major Shareholding Noti…
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 1 page 33.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 notice under the Corporations Act 2001 Section 671B, titled 'Notice of ceasing to be a substantial holder.' It details changes in substantial shareholding, including dates and nature of changes, and is addressed to the company PRESCIENT THERAPEUTICS LIMITED. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category 'Major Shareholding Notification' (MRQ). The document length is short and focused solely on shareholding changes, with no financial statements or other report content.
2019-05-06 English
Change of Director's Interest Notices x4 11 pages 156.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including dates, number of securities acquired or disposed, and nature of changes. The document is a formal notification of personal share transactions by company directors. It does not contain financial performance data, earnings, or management discussion, nor is it an announcement of a report publication. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is substantial and contains detailed transaction data, confirming it is the report itself, not a brief announcement or certification.
2019-05-05 English
Completion of Capital Raising, S708A Notice and Appendix 3B 15 pages 288.1KB
Capital/Financing Update Classification · 100% confidence The document is an ASX release announcing the completion of a capital raising by Prescient Therapeutics Limited, including the issuance of shares and options. It references Section 708A of the Corporations Act and includes an Appendix 3B, which is a standard form for new issue announcements and applications for quotation of additional securities on the ASX. The content focuses on the details of the share issuance, pricing, and compliance with regulatory requirements related to the capital raising. There is no financial performance data, earnings information, or management discussion of results. The document is clearly an update on financing activities and capital structure changes rather than a full financial report or other types of filings. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-05-02 English
Becoming a substantial holder 2 pages 61.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001, detailing the substantial shareholding of Regal Funds Management Pty Ltd in Prescient Therapeutics Limited. It includes voting power, relevant interests, registered holders, consideration paid, and associates. This type of filing is a notification of a major shareholding change, not a financial report, management update, or other corporate filing. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive notification.
2019-05-01 English
Completion of Entitlement Offer Allotment & Appendix 3B 14 pages 288.6KB
Capital/Financing Update Classification · 100% confidence The document is an ASX release announcing the completion of an entitlement offer allotment and includes an Appendix 3B form. The Appendix 3B is a standard ASX form used for new issue announcements, application for quotation of additional securities, and related agreements. The content details the number and class of securities issued, issue price, purpose, and other regulatory compliance information related to the capital raising event. There are no financial statements or detailed financial performance data present, and the document is not a full report but an announcement of a capital raising event and related securities issuance. Therefore, this document fits the category of Capital/Financing Update (CAP).
2019-04-29 English
Entitlement Offer Results and Shortfall Notification 2 pages 130.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 26 April 2019 from Prescient Therapeutics Limited regarding the results of a nonrenounceable entitlement offer and shortfall notification. It details the number of shares applied for, shares issued, underwriting, and the capital structure impact. The content focuses on fundraising activities and changes in the company's capital structure due to the entitlement offer. There are no financial statements or comprehensive financial performance data presented, nor is this a report or presentation. The document is an update on capital raising and share issuance activities, fitting the category of Capital/Financing Update (CAP). The document length is 5667 characters, sufficient to provide substantive detail on the financing event rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2019-04-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.